News
ARGX
993.64
+16.72%
142.35
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Amgen (AMGN)
TipRanks · 7h ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 8h ago
argenx Is Maintained at Overweight by Piper Sandler
Dow Jones · 9h ago
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August
Benzinga · 9h ago
Piper Sandler Maintains Overweight on argenx, Raises Price Target to $1215
Benzinga · 9h ago
Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results
TipRanks · 11h ago
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Benzinga · 11h ago
Argenx rises 14.9%
TipRanks · 11h ago
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
Benzinga · 11h ago
Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal
Benzinga · 11h ago
Argenx: Buy Rating Affirmed on Robust Phase III Vyvgart Myositis Data and Multi-Billion Revenue Potential
TipRanks · 13h ago
At a glance: stocks gapping up premarket
Seeking Alpha · 13h ago
Argenx price target raised to $1,215 from $1,075 at Piper Sandler
TipRanks · 14h ago
Argenx announces ALKIVIA study meets primary endpoint
TipRanks · 15h ago
Weekly Report: what happened at ARGX last week (0810-0814)?
Weekly Report · 15h ago
Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
Seeking Alpha · 16h ago
Argenx Reports Positive Phase 3 Results In Autoimmune Myositis; Stock Up
NASDAQ · 17h ago
Argenx's Efgartigimod Becomes First Phase 3 Therapy To Show Statistically Significant, Clinically Meaningful Improvement In IMNM, A Subtype With No Approved Treatment
Benzinga · 19h ago
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Barchart · 1d ago
Argenx Advances Empasiprubart in Rare Nerve Disorder, Adding Long-Term Upside for ARGX Investors
TipRanks · 4d ago
More
Webull provides a variety of real-time ARGX stock news. You can receive the latest news about Argenx Se through multiple platforms. This information may help you make smarter investment decisions.
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.